Ondek Announces Appointment of Chief Executive Officer
News Mar 19, 2013
Australian drug delivery system company Ondek Limited has announced the appointment of Dr Jenny Harry as Chief Executive Officer.
Ondek is developing innovative ways to deliver medical therapies using the discoveries of Australian Nobel Laureate Barry Marshall.
The Company is currently working to use the stomach bacteria that helped win Dr Marshall the top prize in medicine to fight childhood asthma and allergies.
Ondek Chairman Peter Hammond said, “Dr Harry will play a key role in the global commercialization of Ondek’s novel drug delivery technology. She has already had a significant and positive impact on the business and her experience and skills will be invaluable as we progress through the clinic and negotiate commercial alliances.”
Dr Harry is an experienced CEO of global biotechnology businesses. Before joining Ondek she served as CEO and Managing Director of Tyrian Diagnostics Limited (ASX: TDX) where she led the transformation of the Company from research and development to diagnostics and oversaw commercialization of its first diagnostic products.
She has experience in leading high performing teams, strategic planning and portfolio development, structuring and negotiating agreements with multi-nationals, raising capital for early stage biotechnology companies and investor relations.
Dr Harry has a PhD in developmental biology from Macquarie University, and is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors. Dr Harry is based in Sydney at the offices of Exto Partners Pty Ltd.
Nanoparticles show great promise as diagnostic tools and drug delivery agents. But until now, most nanoparticles had to be injected into the bloodstream because they weren’t absorbed well orally. Now, researchers have modified nanoparticles to improve their uptake in the gastrointestinal tract.